Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Secondary Hyperparathyroidism - Overview
Secondary Hyperparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Secondary Hyperparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
Amgen Inc
Cinkate Corp
EA Pharma Co Ltd
Lupin Ltd
Mitsubishi Tabe Pharma Corp
Novadiol Inc
OPKO Health Inc
Scohia Pharma Inc
TaiRx Inc
Vidasym Inc
Secondary Hyperparathyroidism - Drug Profiles
AJT-240 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
calcifediol ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cicalcet - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTA-091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Secondary Hyperparathyroidism - Dormant Projects
Secondary Hyperparathyroidism - Discontinued Products
Secondary Hyperparathyroidism - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Secondary Hyperparathyroidism, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Secondary Hyperparathyroidism, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Secondary Hyperparathyroidism - Pipeline by Amgen Inc, H2 2020
Secondary Hyperparathyroidism - Pipeline by Cinkate Corp, H2 2020
Secondary Hyperparathyroidism - Pipeline by EA Pharma Co Ltd, H2 2020
Secondary Hyperparathyroidism - Pipeline by Lupin Ltd, H2 2020
Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2020
Secondary Hyperparathyroidism - Pipeline by Novadiol Inc, H2 2020
Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, H2 2020
Secondary Hyperparathyroidism - Pipeline by Scohia Pharma Inc, H2 2020
Secondary Hyperparathyroidism - Pipeline by TaiRx Inc, H2 2020
Secondary Hyperparathyroidism - Pipeline by Vidasym Inc, H2 2020
Secondary Hyperparathyroidism - Dormant Projects, H2 2020
Secondary Hyperparathyroidism - Discontinued Products, H2 2020